Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.40 |
| ▸ | GSK3B | P49841 | 3/20 | 0.36 |
| ▸ | WEE1 | P30291 | 1/20 | 0.35 |
| ▸ | PPOX | P50336 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | HPGD | P15428 | 4/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 4/20 | 0.33 |
| ▸ | MAOB | P27338 | 4/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CDK4 | P11802 | 1/20 | 0.32 |
| ▸ | CCND1 | P24385 | 1/20 | 0.32 |
| ▸ | TYMP | P19971 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7024540 | 0.90 | PARP1 (0.38) | PARP1GSK3BPPOXKDM4EALDH1A1 | |
| SCHEMBL29823991 | 0.90 | PARP1 (0.44) | PARP1GSK3BWEE1PPOXKDM4E | |
| SCHEMBL7687363 | 0.90 | PARP1 (0.44) | PARP1GSK3BWEE1PPOXKDM4E | |
| SCHEMBL9762715 | 0.80 | MAOA (0.44) | PARP1GSK3BMAOAMAOB | |
| SCHEMBL2312949 | 0.75 | PARP1 (0.39) | PARP1GSK3BWEE1PPOXALDH1A1 | |
| SCHEMBL3681061 | 0.74 | PARP1 (0.50) | PARP1GSK3BWEE1PPOXKDM4E | |
| SCHEMBL114048 | 0.73 | PARP1 (0.46) | PARP1GSK3BWEE1PPOXKDM4E | |
| SCHEMBL30969378 | 0.73 | PARP1 (0.46) | PARP1GSK3BWEE1PPOXKDM4E | |
| SCHEMBL28597691 | 0.72 | ELANE (0.40) | PARP1GSK3BKDM4EALDH1A1HPGD | |
| SCHEMBL3781031 | 0.72 | GABRG2 (0.39) | PARP1KDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2361923-A2 | Oligoribonucleotides and ribonucleases for cleaving RNA | Isis Pharmaceuticals, Inc. (US) | 2011-08-31 | — | — | EP | disclosed |
| US-20100151458-A1 | OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA | ISIS PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-7695902-B2 | Oligoribonucleotides and ribonucleases for cleaving RNA | ISIS PHARMACEUTICALS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7629321-B2 | Oligoribonucleotides and oligoribonucleosides that have subsequences of 2'-pentoribofuranosyl nucleosides that activate dsRNase (double stranded RNAase) | ISIS PHARMACEUTICALS, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-7432250-B2 | Oligoribonucleotides and ribonucleases for cleaving RNA | ISIS PHARMACEUTICALS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432249-B2 | Oligoribonucleotides and ribonucleases for cleaving RNA | ISIS PHARMACEUTICALS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20070232798-A1 | Process For The Synthesis Of 2'-O-Substituted Pyrimidines And Oligomeric Compounds Therefrom | COOK PHILLIP D | 2007-10-04 | — | — | US | disclosed |
| EP-1611249-A4 | OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA | ISIS PHARMACEUTICALS INC (US) | 2006-06-28 | — | — | EP | disclosed |
| EP-0813539-B1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 2'-O-SUBSTITUTED PYRIMIDINES AND OLIGOMERIC COMPOUNDS THEREFROM | ISIS PHARMACEUTICALS INC (US) | 2006-05-24 | — | — | EP | disclosed |
| EP-1621545-A2 | Oligoribonucleotides and ribonucleases for cleaving RNA | Isis Pharmaceuticals, Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-0813539-A4 | IMPROVED PROCESS FOR THE SYNTHESIS OF 2'-O-SUBSTITUTED PYRIMIDINES AND OLIGOMERIC COMPOUNDS THEREFROM | ISIS PHARMACEUTICALS INC (US) | 2002-01-23 | — | — | EP | disclosed |
| US-6222025-B1 | OLIGONUCLEOTIDES HAVING 2' AND 5 SUBSTITUTED PYRIMIDINE NUCLEOTIDES; INCREASED AFFINITY FOR NUCLEIC ACIDS; INCREASED NUCLEASE RESISTANCE | ISIS PHARMACEUTICALS, INC. | 2001-04-24 | — | — | US | disclosed |
| US-6166197-A | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions | ISIS PHARMACEUTICALS, INC. (US) | 2000-12-26 | — | — | US | disclosed |
| US-6107094-A | IN VITRO MODIFICATION OF TARGET RNA BY CONTACTING SOLUTION OF TARGET AND RIBONUCLEASE PREFERENTIAL FOR DOUBLE-STRANDED RNA WITH OLIGONUCLEOTIDE COMPLEMENTARY TO TARGET AND INCLUDING NUCLEOTIDES MODIFIED TO IMPROVE AFFINITY/SPECIFICITY | ISIS PHARMACEUTICALS, INC. (US) | 2000-08-22 | — | — | US | disclosed |
| CN-1252795-A | 4, 1-benzoxazepine *, their analogs and their use as somatostatin agonists | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2000-05-10 | — | — | CN | disclosed |
| US-5898031-A | Oligoribonucleotides for cleaving RNA | ISIS PHARMACEUTICALS, INC. (US) | 1999-04-27 | — | — | US | disclosed |
| US-5861493-A | ALKYLATING WITH ALCOHOL IN PRESENCE OF LEWIS ACID; PREPARING OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-19 | — | — | US | disclosed |
| US-5760202-A | TREATING 2,2'-ANHYDROPYRIMIDINE NUCLEOSIDE WITH ALCOHOL AND LEWIS ACID | ISIS PHARMACEUTICALS, INC. (US) | 1998-06-02 | — | — | US | disclosed |
| EP-0813539-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 2'-O-SUBSTITUTED PYRIMIDINES AND OLIGOMERIC COMPOUNDS THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 1997-12-29 | — | — | EP | disclosed |
| WO-1996027606-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 2'-O-SUBSTITUTED PYRIMIDINES AND OLIGOMERIC COMPOUNDS THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 1996-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232798-A1 | Process For The Synthesis Of 2'-O-Substituted Pyrimidines And Oligomeric Compounds Therefrom | TYMS, RRM2, ATIC | PARP1 1158/4885GSK3B 4103/4885WEE1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.